Table of Contents Author Guidelines Submit a Manuscript
Prostate Cancer
Volume 2015, Article ID 285193, 10 pages
http://dx.doi.org/10.1155/2015/285193
Clinical Study

Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients

1Department of Oncology, Wayne State University and Karmanos Cancer Institute, Detroit, MI 48201, USA
2Department of Medicine, Wayne State University, Detroit, MI 48201, USA
3Roger Williams Medical Center, Providence, RI 02908, USA
4Department of Pathology, Roger Williams Medical Center, Providence, RI 02908, USA
5Department of Immunology and Microbiology, Wayne State University, Detroit, MI 48201, USA

Received 10 November 2014; Revised 9 January 2015; Accepted 15 January 2015

Academic Editor: Hendrik Van Poppel

Copyright © 2015 Ulka Vaishampayan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. J. Small, P. F. Schellhammer, C. S. Higano et al., “Placebo-controlled phase III trial of immunologic therapy with Sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer,” Journal of Clinical Oncology, vol. 24, no. 19, pp. 3089–3094, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. Y. Nishio, Y. Yamada, H. Kokubo et al., “Prognostic significance of immunohistochemical expression of the HER-2/neu oncoprotein in bone metastatic prostate cancer,” Urology, vol. 68, no. 1, pp. 110–115, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Ricciardelli, M. W. Jackson, C. S. Choong et al., “Elevated levels of HER-2/neu and androgen receptor in clinically localized prostate cancer identifies metastatic potential,” Prostate, vol. 68, no. 8, pp. 830–838, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Okegawa, M. Kinjo, K. Nutahara, and E. Higashihara, “Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy,” International Journal of Urology, vol. 13, no. 9, pp. 1197–1201, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Signoretti, R. Montironi, J. Manola et al., “Her-2-neu expression and progression toward androgen independence in human prostate cancer,” Journal of the National Cancer Institute, vol. 92, no. 23, pp. 1918–1925, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. I. A. Osman, H. Scher, M. Drobnjak, M. Fazzari, and C. Cordon-Cardo, “HER-2/neu membrane overexpression in prostate cancer,” Proceedings of the American Association for Cancer Research, vol. 41, Article ID 4572a, 2000. View at Google Scholar
  7. N. Craft, Y. Shostak, M. Carey, and C. L. Sawyers, “A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase,” Nature Medicine, vol. 5, no. 3, pp. 280–285, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. P. N. Lara Jr., K. G. Chee, J. Longmate et al., “Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial,” Cancer, vol. 100, no. 10, pp. 2125–2131, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. M. J. Morris, V. E. Reuter, W. K. Kelly et al., “HER-2 profiling and targeting in prostate carcinoma,” Cancer, vol. 94, no. 4, pp. 980–986, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. A. C. Ochoa, G. Gromo, B. J. Alter, P. M. Sondel, and F. H. Bach, “Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, beta-IL 1, interferon-gamma and -beta,” The Journal of Immunology, vol. 138, no. 8, pp. 2728–2733, 1987. View at Google Scholar · View at Scopus
  11. P. M. Anderson, F. H. Bach, and A. C. Ochoa, “Augmentation of cell number and LAK activity in peripheral blood mononuclear cells activated with anti-CD3 and interleukin-2-preliminary results in children with acute lymphocytic leukemia and neuroblastoma,” Cancer Immunology Immunotherapy, vol. 27, no. 1, pp. 82–88, 1988. View at Publisher · View at Google Scholar · View at Scopus
  12. B. P. Chen, M. Malkovsky, J. A. Hank, and P. M. Sondel, “Nonrestricted cytotoxicity mediated by interleukin 2-expanded leukocytes is inhibited by anti-LFA-1 monoclonal antibodies (MoAb) but potentiated by anti-CD3 MoAb,” Cellular Immunology, vol. 110, no. 2, pp. 282–293, 1987. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Lotzova, C. A. Savary, R. B. Herberman, K. B. McCredie, M. J. Keating, and E. J. Freireich, “Augmentation of antileukemia lytic activity by OKT3 monoclonal antibody: synergism of OKT3 and interleukin-2,” Natural Immunity and Cell Growth Regulation, vol. 6, no. 5, pp. 219–223, 1987. View at Google Scholar · View at Scopus
  14. S. C. Yang, K. D. Fry, E. A. Grimm, and J. A. Roth, “Successful combination immunotherapy for the generation in vivo of antitumor activity with anti-CD3, interleukin 2, and tumor necrosis factor α,” Archives of Surgery, vol. 125, no. 2, pp. 220–225, 1990. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Ueda, I. D. Joshi, M. dan et al., “Preclinical studies for adoptive immunotherapy in bone marrow transplantation: generation of anti-CD3 activated cytotoxic T cells from normal donors and autologous bone marrow transplant candidates,” Transplantation, vol. 56, no. 2, pp. 351–356, 1993. View at Publisher · View at Google Scholar · View at Scopus
  16. J. P. Uberti, I. Joshi, M. Ueda, F. Martilotti, L. L. Sensenbrenner, and L. G. Lum, “Preclinical studies using immobilized OKT3 to activate human T cells for adoptive immunotherapy: optimal conditions for the proliferation and induction of non-MHC-restricted cytotoxicity,” Clinical Immunology and Immunopathology, vol. 70, no. 3, pp. 234–240, 1994. View at Publisher · View at Google Scholar · View at Scopus
  17. P. M. Anderson, B. R. Blazar, F. H. Bach, and A. C. Ochoa, “Anti-CD3 + IL-2-stimulated murine killer cells. In vitro generation and in vivo antitumor activity,” The Journal of Immunology, vol. 142, no. 4, pp. 1383–1394, 1989. View at Google Scholar · View at Scopus
  18. P. M. Anderson, A. C. Ochoa, N. K. C. Ramsay, D. Hasz, and D. Weisdorf, “Anti-CD3+ interleukin-2 stimulation of marrow and blood: comparison of proliferation and cytotoxicity,” Blood, vol. 80, no. 7, pp. 1846–1853, 1992. View at Google Scholar · View at Scopus
  19. C.-C. Ting, M. E. Hargrove, and Y. S. Yun, “Augmentation by anti-T3 antibody of the lymphokine-activated killer cell-mediated cytotoxicity,” Journal of Immunology, vol. 141, no. 3, pp. 741–748, 1988. View at Google Scholar · View at Scopus
  20. A. C. Ochoa, D. E. Hasz, R. Rezonzew, P. M. Anderson, and F. H. Bach, “Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: identification and isolation of effector subsets,” Cancer Research, vol. 49, no. 4, pp. 963–968, 1989. View at Google Scholar · View at Scopus
  21. H. E. Lum, M. Miller, D. Van Epps, and L. G. Lum, Targeting Prostate Cancer Cells with T Cells Armed with Two Novel Bispecific Antibodies (OKT3 x 9187 and OKT3 x 9189), 29th edition, 2001.
  22. L. G. Lum, R. Rathore, and H. E. Lum, Targeting of Prostate Cancer with T Cells Armed with OKT3 x Anti-HER2/New Bispecific Monoclonal Antibodies(Biabs), 29 edition, 2001.
  23. P. A. Davol and L. G. Lum, “How important is HER2/neu amplification and expression when selecting patients for HER2/neu-targeted therapies?” Clinical Breast Cancer, vol. 5, no. 1, pp. 70–71, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Sen, D. M. Wankowski, N. K. Garlie et al., “Use of anti-CD3 × anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors,” Journal of Hematotherapy & Stem Cell Research, vol. 10, no. 2, pp. 247–260, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Thakur, D. Schalk, S. H. Sarkar, Z. Al-Khadimi, F. H. Sarkar, and L. G. Lum, “A Th1 cytokine-enriched microenvironment enhances tumor killing by activated T cells armed with bispecific antibodies and inhibits the development of myeloid-derived suppressor cells,” Cancer Immunology, Immunotherapy, vol. 61, no. 4, pp. 497–509, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Thakur, O. Norkina, and L. G. Lum, “In vitro synthesis of primary specific anti-breast cancer antibodies by normal human peripheral blood mononuclear cells,” Cancer Immunology, Immunotherapy, vol. 60, no. 12, pp. 1707–1720, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Thakur, P. Littrup, E. N. Paul, B. Adam, L. K. Heilbrun, and L. G. Lum, “Induction of specific cellular and humoral responses against renal cell carcinoma after combination therapy with cryoablation and granulocyte-macrophage colony stimulating factor: a pilot study,” Journal of Immunotherapy, vol. 34, no. 5, pp. 457–467, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Thakur, D. Schalk, S. H. Sarkar, Z. Al-Khadimi, F. H. Sarkar, and L. G. Lum, “A Th1 cytokine-enriched microenvironment enhances tumor killing by activated T cells armed with bispecific antibodies and inhibits the development of myeloid-derived suppressor cells,” Cancer Immunology, Immunotherapy, vol. 61, no. 4, pp. 497–509, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Thakur, D. Schalk, E. Tomaszewski et al., “Microenvironment generated during EGFR targeted killing of pancreatic tumor cells by ATC inhibits myeloid-derived suppressor cells through COX2 and PGE2 dependent pathway,” Journal of Translational Medicine, vol. 11, no. 1, article 35, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. R. C. Grabert, L. P. Cousens, J. A. Smith et al., “Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation,” Clinical Cancer Research, vol. 12, no. 2, pp. 569–576, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. E. J. Small, N. Sacks, J. Nemunaitis et al., “Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer,” Clinical Cancer Research, vol. 13, no. 13, pp. 3883–3891, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. P. W. Kantoff, T. J. Schuetz, B. A. Blumenstein et al., “Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer,” Journal of Clinical Oncology, vol. 28, no. 7, pp. 1099–1105, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. M. S. Hayden, P. S. Linsley, M. A. Gayle et al., “Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system,” Therapeutic Immunology, vol. 1, no. 1, pp. 3–15, 1994. View at Google Scholar · View at Scopus
  34. M. R. Shalaby, H. M. Shepard, L. Presta et al., “Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene,” Journal of Experimental Medicine, vol. 175, no. 1, pp. 217–225, 1992. View at Publisher · View at Google Scholar · View at Scopus
  35. Z. Zhu, G. D. Lewis, and P. Carter, “Engineering high affinity humanized anti-p185HER2/anti-CD3 F(ab')2 for efficient lysis of p185HER2 overexpressing tumor cells,” International Journal of Cancer, vol. 62, no. 3, pp. 319–324, 1995. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Kuwahara, M. Kuroki, F. Arakawa et al., “A mouse/human-chimeric bispecific antibody reactive with human carcinoembryonic antigen-expressing cells and human T-lymphocytes,” Anticancer Research, vol. 16, no. 5, pp. 2661–2667, 1996. View at Google Scholar · View at Scopus
  37. Y. Nakamura, Y. Tokuda, M. Iwasawa et al., “Large-scale culture system of human CD4+ helper/killer T cells for the application to adoptive tumour immunotherapy,” British Journal of Cancer, vol. 66, no. 1, pp. 20–26, 1992. View at Publisher · View at Google Scholar · View at Scopus
  38. N. D. James, P. J. Atherton, J. Jones, A. J. Howie, S. Tchekmedyian, and R. T. Curnow, “A phase II study of the bispecific antibody MDX-H210 (anti-HER2 x CD64) with GM-CSF in HER2+ advanced prostate cancer,” British Journal of Cancer, vol. 85, no. 2, pp. 152–156, 2001. View at Publisher · View at Google Scholar · View at Scopus